FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in predicting the course of a pathological process in luminal non-hyperexpression of Her2neu primary operable breast cancer in postmenopausal women. That is ensured by determining the androgen receptor expression level in the immunohistochemical examination of the tumor tissue. If observing androgens at 0–4 % and 5–20 %, the aggressive course of luminal Her2neu non-hyperexpression of primary operable breast cancer is predicted.
EFFECT: invention allows predicting the course of luminal non-hyperexpression of Her2neu of primary operable breast cancer in postmenopausal women depending on the level of androgen receptor expression that promotes individual treatment of this category of patients.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
| METHOD FOR PREDICTION OF OCCURRENCE OF LOCAL RECURRENCES IN POSTOPERATIVE PERIOD IN PATIENTS WITH LOCALLY ADVANCED BREAST CANCER | 2020 |
|
RU2734719C1 |
| METHOD OF PREDICTING EFFICIENCY OF CHEMOTHERAPY IN TREATMENT OF MAMMARY GLAND CANCER | 2014 |
|
RU2551232C1 |
| METHOD FOR PREDICTION OF HORMONE-DEPENDENT BREAST CANCER | 2014 |
|
RU2559152C1 |
| METHOD OF PREDICTING RESISTANCE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER | 2022 |
|
RU2802671C1 |
| METHOD FOR PREDICTION OF HORMONE DEPENDENCE OF BREAST CANCER IN PRIMARY MENOPAUSAL PATIENTS | 2014 |
|
RU2562538C2 |
| METHOD FOR PREDICTING RISK OF BREAST CANCER PROGRESSION WITH UNDERLYING TAMOXIFEN TAKING INTO ACCOUNT EXPRESSION CHARACTERISTICS OF TUMOUR | 2023 |
|
RU2823488C1 |
| METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
| METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN | 2017 |
|
RU2648523C1 |
| METHOD FOR PREDICTION OF DEGREE OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LUMINAL MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2632112C1 |
